Sirona Biochem Corp V.SBM

Do not expect a Private Placement

[Transperance]

I do not expect a private placement, but I could be wrong. A private placement would mean mismanagement and that would not benefit the company and its stakeholders. It would not benefit the shareholders and it would not benefit the management group.

If I am wrong then the CFO must be replaced. Liquidity planning and liquidity prognosis is the responsibility of the CFO and he had the full liquidity picture in front of him when the deal was closed. There were excellent opportunities to secure sufficient with funds for the planned company expansion. I expect the funds to be sufficient for Sirona to execute in line with the June 15 NR, including ramp-up and acceleration of the pipeline development in France.

According to the June 15 NR, after the transaction with Abbvie, Sirona stated that, the company will provide continuous information on implemented measures such as:

• Strategic review of every facet of the company including management, organizational structure, project pipeline, financial position and the exchanges on which the Sirona shares are listed.
• Organizational changes and management expansion. External resources will be engaged to assist and there will be updates communicated throughout the remainder of 2022.
• Sirona Biochem will ramp-up and accelerate the pipeline development in France.
• There is a backlog of projects underway and further potential projects that our technology can be applied to. Expertise will be brought in to conduct a review of the lab with the goal to maximize our talent and improve speed to market.
• Up listing remains a goal of Sirona and we are actively taking steps to achieve the necessary requirements.

I expect continuous, quarterly, information from management as to the development and outcome of these bullets. I will follow up that such information is given, going forward.